Navigation Links
Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One
Date:5/5/2010

BIO CONVENTION, CHICAGO, Illinois, May 5, 2010 /PRNewswire/ -- Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI(R) in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.

It has now been discovered that TB does not lie "dormant" but is actually waging a constant war with the host, constantly re-infecting the lungs. Provided that the host is healthy, it has the upper hand and usually keeps the TB in check - LTBI. TB is particularly tricky to eliminate as it can be either replicating, when it can be killed by the antibiotics, or non-replicating when antibiotics are useless. The long, nine month course of antibiotics is needed to ensure that all traces of the non-replicating form are eliminated from the lungs. Further details can be found at http://www.archivelfarma.com/hipotesi_an.html

Archivel's novel, two pronged approach combines a one month course of antibiotic to eliminate the bacteria in the replicating stage and two injections of the company's RUTI vaccine that stimulates the body's own immune system to fight the TB bacteria. This combination approach reduces the treatment time from nine months to one, is easier to manage, less expensive, more effective and more likely to be done comple
'/>"/>

SOURCE Archivel Farma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Anthrax vaccine produces immunity with nanoparticles, not needles
5. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
6. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. New nanoparticle vaccine is more effective but less expensive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... RURO, Inc., a leading LIMS, RFID ... the latest major content upgrade to its bestselling, Commercial ... Upgrade is a significant advancement of FreezerPro® system ... experience, while also simplifying , New ... Download available immediately for free to “Gold” ...
(Date:5/5/2015)... 2015  Blueprint Medicines (NASDAQ: BPMC ) ... offering of 9,367,708 shares of common stock at ... including shares of common stock issued upon the ... to purchase additional shares. The gross proceeds from ... approximately $168.6 million, before underwriting discounts and estimated offering ...
(Date:5/5/2015)... May 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... results for the three months ended March 31, 2015 ... amounts are in Canadian dollars. Effective ... end from May 31 to December 31. As a ... reported is for the three months ended March 31, ...
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens,  today announced that Paul G. Thomas ... 2015 Health Care Conference on May 12 at 8:00am PT. ... Las Vegas NV. ... the investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:RURO Releases version 7 of FreezerPro® software 2Blueprint Medicines Announces Closing of Initial Public Offering 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8
... ROCKVILLE, Md., Feb. 11 OriGene Technologies, Inc. ... $6.5 million in a private equity financing. With ... assets of privately held Shenzhen P&A Biotech, a ... the research community. With this acquisition OriGene completes ...
... N.Y., Feb. 11 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... and Mr. Boaz Shweiger have been appointed to XTL,s ... will also be assuming,the role of Co-Chief Executive Officer, ... strategic alternatives. , Ron Bentsur, ...
... Ferring Research Institute Introduce New Research Base and ... DiegoSAN DIEGO, Feb. 11 Leading global biopharmaceutical ... Institute have opened a new and expanded, 38,000-square-foot ... will be dedicated to further development of peptide ...
Cached Biology Technology:OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 2Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 3Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix 4
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... 2013 Dr. Jeffrey Trent, President and Research Director ... state-of-the-art genomics research July 16 at the Brookings Institution. ... Director of the National Human Genome Research Institute, is ... 2nd annual State of Biomedical Innovation Conference, which will ...
... At the end of the last Ice Age, as the ... Ocean came to life. During a brief pulse of biological ... with phytoplankton, amoeba-like foraminifera and other tiny creatures, who thrived ... beganjust a few hundred years later. Researchers have ...
... may prevent key grassland species from taking hold and ... has shown., Work by scientists at Newcastle University, UK, ... biodiversity and how this might inform future restoration work., ... gardener,s prize petunias or strawberry patch, still relatively little ...
Cached Biology News:TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference 2Scientists solve a 14,000-year-old ocean mystery 2Scientists solve a 14,000-year-old ocean mystery 3Grazing slugs hinder grassland restoration 2
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
... membrane filters suitable for use in the Microsart ... of each filter, in a specially designed individual ... pleating of the band of membrane filter units ... The shape of the sealed band guarantees uniform ...
... The model 55S Rocking Shaker provides ... and blotted membranes. The very slow ... degree of tilt provide a gentle ... over gels and blotted membranes to ...
Biology Products: